Pyxis Oncology Q3 net loss narrows to $20.0 million from $22.0 million
Pyxis Oncology reported a third-quarter 2026 net loss of $20.0 million, or $0.24 per share, down from $22.0 million, or $0.35 per share, a year earlier. The company reported no revenue in either quarter, and it held $57.0 million in cash and short-term investments at September 30, 2026. It says an October 1, 2026 public offering with about $110.0 million in upfront gross proceeds should fund operations into the first half of 2028.
Key points
- Net loss was $20.0 million, or $(0.24) per share, for the quarter ended September 30, 2026, versus $22.0 million, or $(0.35) per share, a year earlier.
- Research and development expenses were $16.6 million, down from $17.8 million; general and administrative expenses were $4.0 million, down from $5.7 million.
- Cash and short-term investments were $57.0 million at September 30, 2026; the October 2026 offering included milestone-linked warrants that could add about $172.6 million if exercised in full.
- FDA feedback on dose selection is expected in the first quarter of 2027, and the global Phase 3 Headliner SM trial is planned to start in mid-2027.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.